UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The Lancet (British edition), ISSN 0140-6736, 06/2018, Volume 391, Issue 10139, pp. 2513 - 2524
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Severity of Illness Index | Double-Blind Method | Antirheumatic Agents - administration & dosage | Heterocyclic Compounds, 3-Ring - pharmacology | Humans | Middle Aged | Delayed-Action Preparations - administration & dosage | Dose-Response Relationship, Drug | Janus Kinase Inhibitors - adverse effects | Janus Kinase Inhibitors - pharmacology | Janus Kinase Inhibitors - administration & dosage | Arthritis, Rheumatoid - drug therapy | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Methotrexate - administration & dosage | Aged | Rheumatoid factor | Care and treatment | Antirheumatic agents | Analysis | Clinical trials | Product development | Arthritis | Pharmaceutical industry | Drugs | C-reactive protein | Rhinopharyngitis | Infections | Urinary tract | Kinases | Evidence-based medicine | Skin cancer | Proteins | Respiratory tract | Randomization | Motivation | Janus kinase | Respiratory tract diseases | Tumor necrosis factor-TNF | Safety | Herpes zoster | Effectiveness | Medical treatment | Rheumatology | Disease control | Patients | Embolism | Studies | Intolerance | Rheumatoid arthritis | TNF inhibitors | Health risk assessment | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article
AIDS (London), 08/2017, Volume 31, Issue 13, p. 1853
Raltegravir Potassium - adverse effects | Mental Disorders - epidemiology | Prospective Studies | Mental Disorders - chemically induced | Anti-HIV Agents - adverse effects | Humans | Middle Aged | Raltegravir Potassium - administration & dosage | Male | Withholding Treatment | Switzerland | Drug-Related Side Effects and Adverse Reactions - epidemiology | Anti-HIV Agents - administration & dosage | Young Adult | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Adolescent | Aged, 80 and over | Adult | Female | HIV Infections - drug therapy | Aged
Journal Article
The Lancet (British edition), ISSN 0140-6736, 06/2018, Volume 391, Issue 10139, pp. 2503 - 2512
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Severity of Illness Index | Double-Blind Method | Antirheumatic Agents - administration & dosage | Heterocyclic Compounds, 3-Ring - pharmacology | Humans | Middle Aged | Male | Disease Progression | Janus Kinase Inhibitors - adverse effects | Janus Kinase Inhibitors - pharmacology | Janus Kinase Inhibitors - administration & dosage | Arthritis, Rheumatoid - drug therapy | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Adult | Female | Methotrexate - administration & dosage | Aged | Rheumatoid factor | Care and treatment | Antirheumatic agents | Analysis | Clinical trials | Arthritis | Product development | Drugs | Headache | C-reactive protein | Viruses | Rhinopharyngitis | Infections | Leflunomide | Evidence-based medicine | Regulatory approval | Skin cancer | Proteins | Respiratory tract | Randomization | Varicella | Rheumatism | Janus kinase | Respiratory tract diseases | Sulfasalazine | Tumor necrosis factor-TNF | Methotrexate | Drug dosages | Signs and symptoms | Herpes zoster | Effectiveness | Rheumatology | Melanoma | Nausea | Disease control | Patients | Studies | Rheumatoid arthritis | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 12/2011, Volume 29, Issue 35, pp. 4688 - 4695
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Neoplasms - metabolism | Protein Kinase Inhibitors - pharmacokinetics | Humans | Middle Aged | Neoplasms - enzymology | Male | Protein Kinase Inhibitors - adverse effects | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - administration & dosage | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Aged, 80 and over | Adult | Female | Aged | Heterocyclic Compounds, 3-Ring - pharmacokinetics | Neoplasms - pathology | Proto-Oncogene Proteins c-akt - metabolism | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Index Medicus
Journal Article
Clinical pharmacokinetics, ISSN 0312-5963, 12/2016, Volume 55, Issue 12, pp. 1547 - 1558
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Drug Administration Schedule | Administration, Oral | Antirheumatic Agents - administration & dosage | Area Under Curve | Humans | Middle Aged | Half-Life | Male | Metabolic Clearance Rate | Healthy Volunteers | Janus Kinase 1 - antagonists & inhibitors | Young Adult | Arthritis, Rheumatoid - drug therapy | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Adolescent | Antirheumatic Agents - adverse effects | Adult | Antirheumatic Agents - pharmacokinetics | Female | Aged | Heterocyclic Compounds, 3-Ring - pharmacokinetics | Antirheumatic Agents - therapeutic use
Journal Article
Clinical cancer research, ISSN 1078-0432, 11/2014, Volume 20, Issue 22, pp. 5672 - 5685
Life Sciences & Biomedicine | Oncology | Science & Technology | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Neoplasms - diagnosis | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Heterocyclic Compounds, 3-Ring - pharmacokinetics | Biomarkers - metabolism | Protein Kinase Inhibitors - pharmacokinetics | Drug Administration Schedule | Treatment Outcome | Neoplasms - drug therapy | Diagnostic Imaging | Magnetic Resonance Imaging | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Protein Kinase Inhibitors - therapeutic use | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Aged | Drug Monitoring | Neoplasm Staging | Neoplasms - pathology | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Index Medicus
Journal Article
AIDS (London), ISSN 0269-9370, 09/2011, Volume 25, Issue 14, pp. 1737 - 1745
pharmacokinetics | dose response | antiretroviral therapy | pharmacodynamics | integrase inhibitor | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | Virology | Antiviral agents | Immunopathology | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Immunodeficiencies. Immunoglobulinopathies | Immunodeficiencies | Antibiotics. Antiinfectious agents. Antiparasitic agents | Anti-HIV Agents - pharmacology | Double-Blind Method | Drug Administration Schedule | Area Under Curve | HIV-1 - drug effects | Heterocyclic Compounds, 3-Ring - pharmacology | Anti-HIV Agents - adverse effects | Humans | Middle Aged | Male | Treatment Outcome | Dose-Response Relationship, Drug | Anti-HIV Agents - pharmacokinetics | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Heterocyclic Compounds, 3-Ring - pharmacokinetics | Index Medicus | AIDS/HIV
Journal Article
The Journal of infectious diseases, ISSN 0022-1899, 3/2013, Volume 207, Issue 5, pp. 740 - 748
MAJOR ARTICLES AND BRIEF REPORTS | S/GSK1349572 | DTG | integrase inhibitor | Dolutegravir | raltegravir resistance | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Miscellaneous | Infectious diseases | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Virology | Anti-HIV Agents - pharmacology | Heterocyclic Compounds, 3-Ring - pharmacology | Humans | Middle Aged | Drug Resistance, Viral | Male | RNA, Viral - blood | Viral Load | Anti-HIV Agents - administration & dosage | Young Adult | HIV-1 - isolation & purification | Pyrrolidinones - pharmacology | Adult | Female | Antiretroviral Therapy, Highly Active - methods | Raltegravir Potassium | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | HIV Infections - virology | Treatment Outcome | Plasma - virology | Pilot Projects | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | HIV Infections - drug therapy | Aged | Index Medicus | Abridged Index Medicus | Major and Brief Reports | GSK1349572
Journal Article
Hepatology (Baltimore, Md.), ISSN 0270-9139, 12/2013, Volume 58, Issue 6, pp. 1918 - 1929
Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Simeprevir | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | Ribavirin - administration & dosage | Adult | Female | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Ribavirin - adverse effects | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Adolescent | Sulfonamides - adverse effects | Aged | Interferon-alpha - adverse effects | Viral Load - drug effects | Sulfonamides - administration & dosage | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 383, Issue 9936, pp. 2222 - 2231
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | HIV-1 | Darunavir | Drug Administration Schedule | Ritonavir - administration & dosage | Anti-HIV Agents - adverse effects | Humans | Middle Aged | Male | Treatment Outcome | Anti-HIV Agents - administration & dosage | Young Adult | Creatinine - metabolism | Ritonavir - adverse effects | Analysis of Variance | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Adolescent | Sulfonamides - adverse effects | Adult | Female | HIV Infections - drug therapy | Aged | Sulfonamides - administration & dosage | Serum Albumin - metabolism | Dosage and administration | Research | Drug therapy | Comparative analysis | HIV infection | Antiretroviral drugs | Mutation | Drug dosages | Human immunodeficiency virus--HIV | Index Medicus | Abridged Index Medicus
Journal Article
11.
A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir
Clinical pharmacokinetics, ISSN 0312-5963, 06/2017, Volume 56, Issue 6, pp. 661 - 669
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | HIV Integrase Inhibitors - pharmacology | Triazoles - adverse effects | Triazoles - blood | Reverse Transcriptase Inhibitors - blood | Area Under Curve | Heterocyclic Compounds, 3-Ring - pharmacology | Humans | Reverse Transcriptase Inhibitors - pharmacology | Male | Pyridones - blood | Reverse Transcriptase Inhibitors - adverse effects | Young Adult | Reverse Transcriptase Inhibitors - pharmacokinetics | Drug Interactions | Adult | Female | Triazoles - pharmacokinetics | Fasting - metabolism | Drug Therapy, Combination | Heterocyclic Compounds, 3-Ring - pharmacokinetics | Pyridones - pharmacokinetics | HIV Integrase Inhibitors - pharmacokinetics | Triazoles - pharmacology | HIV Integrase Inhibitors - adverse effects | Heterocyclic Compounds, 3-Ring - blood | Heterocyclic Compounds, 3-Ring - adverse effects | HIV Integrase Inhibitors - blood | Pyridones - adverse effects | Pyridones - pharmacology
Journal Article